Fate Therapeutics (FATE) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 12, 2026, at the company’s San Diego headquarters.

• Stockholders of record as of April 15, 2026, are eligible to vote on key proposals.

• Proxy materials, including the proxy statement and annual report, are available online and by request.

Voting matters and shareholder proposals

• Election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Proposal to amend and restate the 2022 Stock Option and Incentive Plan to increase reserved shares.

• Additional business may be transacted as appropriate at the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all four proposals presented.